Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
86%(6 trials)

Phase Distribution

Ph phase_4
1
13%
Ph phase_2
2
25%
Ph phase_3
5
63%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
5(62.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Other(1)

Detailed Status

Completed7
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 35 (62.5%)
Phase 41 (12.5%)

Trials by Status

unknown113%
completed788%

Recent Activity

0 active trials
Showing 5 of 8
unknownphase_3

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

NCT04808531
completedphase_2

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
completedphase_4

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

NCT00955110
completedphase_3

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

NCT01165281
completedphase_2

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

NCT00979953
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04808531Phase 3

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

Unknown
NCT01709214Phase 2

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Completed
NCT00955110Phase 4

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Completed
NCT01165281Phase 3

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Completed
NCT00979953Phase 2

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

Completed
NCT00361504Phase 3

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Completed
NCT00449176Phase 3

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Completed
NCT00784277Phase 3

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8